Literature DB >> 6793632

Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

R B Fick, G P Naegel, R A Matthay, H Y Reynolds.   

Abstract

Pseudomonas aeruginosa infection plays a primary pathogenetic role in the chronic respiratory tract disease of cystic fibrosis (CF) patients. Despite pronounced humoral immune responses, reflected by high levels of antibodies against Pseudomonas in serum and in sputum, the antibodies do not eliminate this bacterium. In the present study we have used affinity chromatography with a lipopolysaccharide substituted immunoadsorbent gel to isolate high titers (meanCF = 1:256) of immunotype specific Pseudomonas IgG antibodies from the sera of nine CF subjects, and have evaluated the functional ability of these antibodies to promote phagocytosis and intracellular killing of P. aeruginosa in an in vitro human alveolar macrophage culture system. The phagocytic and intracellular bactericidal kinetics revealed that CF IgG antibodies function in an inhibitory fashion. Both the rate of phagocytosis (rateCF = 204 cpm/unit time) and absolute bacterial uptakes maximal at 120 min (uptakeCF = 18 x 10(3) 14C cpm) were inhibited compared with appropriate positive controls (hyperimmune serum, HIS; [rateHIS = 399; uptakeHIS = 29 x 10(3), P less than 0.005]). The ability of such CF-derived opsonins to potentiate macrophage intracellular bactericidal processes was mildly impaired (bacterial survivalCF = 15 x 10(3) colony forming units (CFU)/min, survivalHIS = 9 x 10(3)). Further characterization of this defect, assessed with functional studies of the Fab and Fc portions of the immunoglobulin molecule, revealed an impairment in the attachment of these specific antibodies to the alveolar macrophage membrane Fc gamma receptors. Preliminary studies of the physical-chemical properties of these immunoglobulins were normal. The expression of this inhibitory activity in vivo may facilitate Pseudomonas colonization and the subsequent established infections in the respiratory tracts of CF subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6793632      PMCID: PMC370877          DOI: 10.1172/jci110345

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  A quantitative immunochemical measure of the primary interaction between I BSA and antibody.

Authors:  R S FARR
Journal:  J Infect Dis       Date:  1958 Nov-Dec       Impact factor: 5.226

2.  Studies on the immunoglobulins which stimulate the ingestion of glutaraldehyde-treated red cells attached to macrophages.

Authors:  M Rabinovitch
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

3.  Structural units of canine serum and secretory immunoglobulin A.

Authors:  H Y Reynolds; J S Johnson
Journal:  Biochemistry       Date:  1971-07-20       Impact factor: 3.162

4.  Immunological aspects of cystic fibrosis.

Authors:  S P Halbert
Journal:  Bibl Paediatr       Date:  1967

5.  Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine.

Authors:  S Hanessian; W Regan; D Watson; T H Haskell
Journal:  Nat New Biol       Date:  1971-02-17

6.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

7.  Opsonic defect in patients with cystic fibrosis of the pancreas.

Authors:  W D Biggar; B Holmes; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

8.  The human alveolar macrophage: isolation, cultivation in vitro, and studies of morphologic and functional characteristics.

Authors:  A B Cohen; M J Cline
Journal:  J Clin Invest       Date:  1971-07       Impact factor: 14.808

9.  Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies.

Authors:  R B Fick; G P Naegel; H Y Reynolds
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

10.  Ultrastructure and function of alveolar macrophages from cystic fibrosis patients.

Authors:  M J Thomassen; C A Demko; R E Wood; B Tandler; D G Dearborn; B Boxerbaum; P J Kuchenbrod
Journal:  Pediatr Res       Date:  1980-05       Impact factor: 3.756

View more
  26 in total

1.  Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

Authors:  O Ciofu; T D Petersen; P Jensen; N Høiby
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function.

Authors:  J E Salmon; J C Edberg; N L Brogle; R P Kimberly
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

Review 3.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

4.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.

Authors:  T R Shryock; J S Mollé; J D Klinger; M J Thomassen
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

6.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

7.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats.

Authors:  M J Thomassen; J D Klinger; G B Winnie; R E Wood; C Burtner; J F Tomashefski; J G Horowitz; B Tandler
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

Review 9.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 10.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.